Brought to you by 
Servier options rights to three of MacroGenics' DART compounds; deal ends
05 Oct 2021
Executive Summary
Building on a relationship that began with a separate deal almost a year ago, Servier SA has once again optioned rights to early-stage projects from MacroGenics Inc. (therapies for autoimmune and infectious diseases and cancer). This time, the French pharmaco has its sights on three of MacroGenics’ preclinical anticancer DART (Dual-Affinity Re-Targeting) compounds.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Immuno-Oncology
-
Large Molecule
- Antibodies
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Contract
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com